The ulcerative
colitis pipeline analysis report
covers approximately 89 drug candidates in different stages of development.
Ulcerative
colitis is a chronic inflammatory disease, which basically affect colonic
mucosa. The main identified symptoms of the disease are bloody diarrhea,
abdominal cramps and fatigue. Some of the other symptoms include, fever,
vomiting, anorexia, abdominal distension and bloating. The treatment approaches
to this disease mostly include the use of small molecules and monoclonal
antibodies, which are being developed to target and reduce the inflammatory
mediators.
Download
Free Sample of This Research Report: https://www.psmarketresearch.com/market-analysis/ulcerative-colitis-pipeline-analysis/report-sample
The
research found that different companies are engaged in the collaboration for
ulcerative colitis. In June, 2015 Lycera Corp. and Celgene Corporation
collaborated for the development of Lycera Corp. drug candidate for the
treatment of ulcerative colitis. Celgene obtained the exclusive right to
acquire Lycera upon conclusion of the option period or achievement by Lycera of
pre-specified clinical milestones. During the option period, Lycera retained
full control of its research and development programs.
Make
Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=ulcerative-colitis-pipeline-analysis
Some of
the key players developing ulcerative colitis therapeutics include EA Pharma
Co., Ltd., Celgene Corporation, InDex Pharmaceuticals AB and others.
Ulcerative
Colitis Pipeline Analysis
- By Phase
- By Route of Administration
- By Molecule Type
- By Company
Contact:
Mr. Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886
(USA/Canada)
Email: enquiry@psmarketresearch.com
No comments:
Post a Comment